NEWS 18 MAY 22 CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:55:55 ON 10 JUL 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:56:08 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4
DICTIONARY FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10549546b.str





chain nodes :
7 8 9 10 12 13 14 22
ring nodes :
1 2 3 4 5 6 11 15 16 17 18
chain bonds :
6-7 7-8 7-13 7-14 8-9 8-22 9-10 10-11 10-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-15 11-18 15-16 16-17 17-18
exact/norm bonds :
6-7 7-8 7-13 7-14 8-9 8-22 9-10 10-11 10-12 11-15 11-18 15-16 16-17
17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom
22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:57:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2186 TO ITERATE

91.5% PROCESSED 2000 ITERATIONS 20 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 40916 TO 46524
PROJECTED ANSWERS: 157 TO 717

L2 20 SEA SSS SAM L1

=> d scan

L2 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(6-nitro-3-pyridinyl)- (9CI)
MF C23 H31 N5 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI)
MF C21 H31 Cl3 N4 O4 S . 2 C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l1 full
FULL SEARCH INITIATED 09:57:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    43351 TO ITERATE

100.0% PROCESSED    43351 ITERATIONS                          369 ANSWERS
SEARCH TIME: 00.00.01

L3          369 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               173.00     173.21

FILE 'CAPLUS' ENTERED AT 09:57:54 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 10 Jul 2007  VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007  (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4          18 L3

=> d l4 1-18
```

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:259671 CAPLUS
DN 146:297694
TI Biocompatible cyanine fluorescent imaging agents and method of in vivo optical imaging
IN Rajopadhye, Milind; Groves, Kevin
PA Visen Medical, Inc., USA
SO PCT Int. Appl., 98pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007028163	A1	20070308	WO 2006-US34604	20060901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-714075P P 20050902
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:610647 CAPLUS
DN 145:224314
TI Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: hydroxamic acid analogs
AU Gupta, S. P.; Kumaran, S.
CS Department of Chemistry, Birla Institute of Technology and Science, Pilani, 333031, India
SO Medicinal Chemistry (2006), 2(3), 243-250
CODEN: MCEHAJ; ISSN: 1573-4064
PB Bentham Science Publishers Ltd.
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:241640 CAPLUS
DN 142:463562
TI Synthesis of 3-Arylpiperidines by a Radical 1,4-Aryl Migration
AU Gheorghe, Alexandru; Quiclet-Sire, Beatrice; Vila, Xavier; Zard, Samir Z.
CS Laboratoire de Synthese Organique, Departement de Chimie, Ecole Polytechnique, Palaiseau, 91128, Fr.
SO Organic Letters (2005), 7(8), 1653-1656
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:463562
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:857596 CAPLUS
DN 141:350198
TI Heterocyclic (piperazine- and piperidine-containing) benzenesulfonamide derivatives, method for their production, therapeutic compositions, and use thereof for treatment of pain and inflammation
IN Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean-Michel
PA Laboratoires Fournier S.A., Fr.
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087700	A1	20041014	WO 2004-FR723	20040324
	WO 2004087700	A8	20041118		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2852958	A1	20041001	FR 2003-3602	20030325
	FR 2852958	B1	20050624		
	FR 2853648	A1	20041015	FR 2003-4530	20030411
	FR 2853648	B1	20060818		
	AU 2004226197	A1	20041014	AU 2004-226197	20040324
	CA 2519110	A1	20041014	CA 2004-2519110	20040324
	EP 1606288	A1	20051221	EP 2004-742333	20040324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008689	A	20060328	BR 2004-8689	20040324
	JP 2006521333	T	20060921	JP 2006-505749	20040324
	US 2006178360	A1	20060810	US 2005-549546	20050914
	NO 2005004361	A	20051101	NO 2005-4361	20050920
PRAI	FR 2003-3602	A	20030325		
	FR 2003-4530	A	20030411		
	WO 2004-FR723	A	20040324		

OS MARPAT 141:350198
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:800854 CAPLUS
DN 141:314016
TI Preparation of benzenesulfonamides as Bradykinin B1 receptors antagonists for treatment of pain and inflammation
IN Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean Michel
PA Laboratoires Fournier S.A., Fr.
SO Fr. Demande, 27 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2852958	A1	20041001	FR 2003-3602	20030325
	FR 2852958	B1	20050624		
	AU 2004226197	A1	20041014	AU 2004-226197	20040324
	CA 2519110	A1	20041014	CA 2004-2519110	20040324
	WO 2004087700	A1	20041014	WO 2004-FR723	20040324
	WO 2004087700	A8	20041118		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1606288	A1	20051221	EP 2004-742333	20040324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008689	A	20060328	BR 2004-8689	20040324
	CN 1764661	A	20060426	CN 2004-80007762	20040324
	JP 2006521333	T	20060921	JP 2006-505749	20040324
	NO 2005004361	A	20051101	NO 2005-4361	20050920
PRAI	FR 2003-3602	A	20030325		
	FR 2003-4530	A	20030411		
	WO 2004-FR723	A	20040324		

OS MARPAT 141:314016
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:349769 CAPLUS
DN 141:71820
TI Synthesis of Cyclic Peptidosulfonamides by Ring-Closing Metathesis
AU Brouwer, Arwin J.; Liskamp, Rob M. J.
CS Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NL-3508 TB, Neth.
SO Journal of Organic Chemistry (2004), 69(11), 3662-3668
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:71820
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:485895 CAPLUS
DN 139:223711
TI Novel inhibitors of procollagen C-Proteinase. Part 2: glutamic acid hydroxamates
AU Robinson, L. A.; Wilson, D. M.; Delaet, N. G. J.; Bradley, E. K.; Dankwardt, S. M.; Campbell, J. A.; Martin, R. L.; Van Wart, H. E.; Walker, K. A. M.; Sullivan, R. W.
CS CombiChem Inc., San Diego, CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2381-2384
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:223711
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:441768 CAPLUS
DN 133:74324
TI Preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase.
IN Billedeau, Roland Joseph; Broka, Chris Allen; Campbell, Jeffrey Allen; Chen, Jian Jeffrey; Dankwardt, Sharon Marie; Delaet, Nancy; Robinson, Leslie Ann; Walker, Keith Adrian Murray
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000037436	A1	20000629	WO 1999-EP9920	19991214
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2355902	A1	20000629	CA 1999-2355902	19991214
	BR 9916504	A	20010911	BR 1999-16504	19991214
	EP 1149072	A1	20011031	EP 1999-963530	19991214
	EP 1149072	B1	20040630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101868	T2	20011121	TR 2001-200101868	19991214
	HU 200104658	A2	20020629	HU 2001-4658	19991214
	JP 2002533322	T	20021008	JP 2000-589508	19991214
	AU 769319	B2	20040122	AU 2000-19792	19991214
	NZ 512292	A	20040326	NZ 1999-512292	19991214
	AT 270271	T	20040715	AT 1999-963530	19991214
	RU 2232751	C2	20040720	RU 2001-119461	19991214
	US 6492394	B1	20021210	US 1999-469660	19991222
	HR 2001000443	A1	20020630	HR 2001-443	20010614
	ZA 2001005014	A	20020919	ZA 2001-5014	20010619
	MX 2001PA06328	A	20010910	MX 2001-PA6328	20010620
	IN 2001CN00859	A	20050304	IN 2001-CN859	20010620
	NO 2001003100	A	20010821	NO 2001-3100	20010621
	US 2003199520	A1	20031023	US 2002-267292	20021009
	US 6844366	B2	20050118		
	US 2003216405	A1	20031120	US 2002-267727	20021009
	US 6787559	B2	20040907		
PRAI	US 1998-113311P	P	19981222		
	US 1999-147053P	P	19990803		
	US 1999-164138P	P	19991108		
	WO 1999-EP9920	W	19991214		
	US 1999-469660	A3	19991222		

OS MARPAT 133:74324
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:96004 CAPLUS
DN 132:151682
TI Preparation of sulfonylaminoalkanediamides and related compounds as matrix metalloproteinase inhibitors.
IN Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PA British Biotech Pharmaceuticals Ltd., UK
SO U.S., 32 pp., Cont.-in-part of Ser. No. Wo97GB-9702891.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6022873	A	20000208	US 1998-121033	19980723
	WO 9817655	A1	19980430	WO 1997-GB2891	19971020
	W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	PT 1030842	T	20030731	PT 1997-912351	19971113
	ES 2195122	T3	20031201	ES 1997-912351	19971113
PRAI	GB 1996-21814	A	19961019		
	WO 1997-GB2891	A2	19971020		
	EP 1997-912351	A	19971113		

OS MARPAT 132:151682
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:662331 CAPLUS
DN 132:30315
TI The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors
AU Martin, Fionna M.; Beckett, R. Paul; Bellamy, Claire L.; Courtney, Paul F.; Davies, Stephen J.; Drummond, Alan H.; Dodd, Rory; Pratt, Lisa M.; Patel, Sanjay R.; Ricketts, Michelle L.; Todd, Richard S.; Tuffnell, Andrew R.; Ward, John W. S.; Whittaker, Mark
CS British Biotech Pharmaceuticals Limited, Oxford, OX4 5LY, UK
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(19), 2887-2892
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:626184 CAPLUS
DN 131:242793
TI Preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors
IN Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon
PA British Biotech Pharmaceuticals Limited, UK
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9948881	A1	19990930	WO 1998-GB914	19980325
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9868435	A	19991018	AU 1998-68435	19980325
	EP 1066273	A1	20010110	EP 1998-913910	19980325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2003522723	T	20030729	JP 2000-537864	19980325
PRAI	WO 1998-GB914	A	19980325		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:460409 CAPLUS
DN 131:87805
TI Preparation of amprenavir prodrugs as HIV protease inhibitors
IN Tung, Roger D.; Hale, Michael R.; Baker, Christopher T.; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Wieczyslaw; Spaltenstein, Andrew
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933815	A1	19990708	WO 1998-US4595	19980309
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6436989	B1	20020820	US 1997-998050	19971224
	AU 9865466	A	19990719	AU 1998-65466	19980309
	AU 755087	B2	20021205		
	TR 200002615	T2	20010122	TR 2000-200002615	19980309
	BR 9814480	A	20010925	BR 1998-14480	19980309
	EE 200000385	A	20011217	EE 2000-385	19980309
	EE 4466	B1	20050415		
	HU 200101831	A2	20020429	HU 2001-1831	19980309
	HU 200101831	A3	20020828		
	AP 1172	A	20030630	AP 2000-1850	19980309
	W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
	NZ 505776	A	20030630	NZ 1998-505776	19980309
	CA 2231700	C	19990624	CA 1998-2231700	19980310
	CA 2231700	A1	19990624		
	JP 11209337	A	19990803	JP 1998-58705	19980310
	JP 3736964	B2	20060118		
	EP 933372	A1	19990804	EP 1998-104292	19980310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TW 486474	B	20020511	TW 1998-87121460	19981222
	ZA 9811830	A	20000623	ZA 1998-11830	19981223
	IN 1998CA02210	A	20051014	IN 1998-CA2210	19981223
	NO 2000003304	A	20000821	NO 2000-3304	20000623
	MX 2000PA06315	A	20010219	MX 2000-PA6315	20000623
	US 6559137	B1	20030506	US 2000-602494	20000623
	BG 104631	A	20010228	BG 2000-104631	20000724
	BG 64869	B1	20060731		
	US 2003207871	A1	20031106	US 2003-370171	20030219
	US 6838474	B2	20050104		
	US 2005148548	A1	20050707	US 2004-958223	20041004
	JP 2005350478	A	20051222	JP 2005-205007	20050713
PRAI	US 1997-998050	A2	19971224		
	WO 1998-US4595	W	19980309		
	JP 1998-58705	A3	19980310		
	US 2000-602494	A3	20000623		
	US 2003-370171	A3	20030219		

OS MARPAT 131:87805

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:460393 CAPLUS
DN 131:87804
TI Preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
IN Hale, Michael R.; Tung, Roger D.; Baker, Christopher T.; Spaltenstein, Andrew; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933793	A2	19990708	WO 1998-US27424	19981223
	WO 9933793	A3	19990910		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2316218	A1	19990708	CA 1998-2316218	19981223
	AU 9920925	A	19990719	AU 1999-20925	19981223
	BR 9814484	A	20001010	BR 1998-14484	19981223
	EP 1042280	A2	20001011	EP 1998-965466	19981223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200002402	T2	20010122	TR 2000-200002402	19981223
	EE 200000386	A	20011217	EE 2000-386	19981223
	JP 2001527062	T	20011225	JP 2000-526477	19981223
	HU 200101598	A2	20020429	HU 2001-1598	19981223
	HU 200101598	A3	20020828		
	CN 1110492	B	20030604	CN 1998-813313	19981223
	MX 2000PA06316	A	20010219	MX 2000-PA6316	20000623
	NO 2000003332	A	20000818	NO 2000-3332	20000626
	IN 2000KN00131	A	20050311	IN 2000-KN131	20000713
	HR 2000000499	A1	20010430	HR 2000-499	20000724
	US 2002082249	A1	20020627	US 2001-998617	20011130
	US 2003144217	A1	20030731	US 2002-226430	20020821
PRAI	US 1997-68889P	P	19971224		
	WO 1998-US27424	W	19981223		
	US 2000-602984	A1	20000623		
	US 2001-998617	B1	20011130		

OS MARPAT 131:87804

L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:460392 CAPLUS
DN 131:87803
TI Preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
IN Hale, Michael R.; Tung, Roger D.; Baker, Christopher T.; Spaltenstein, Andrew; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933792	A2	19990708	WO 1998-US27403	19981223
	WO 9933792	A3	19990916		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9920102	A	19990719	AU 1999-20102	19981223
PRAI	US 1997-68806P	P	19971224		
	WO 1998-US27403	W	19981223		

OS MARPAT 131:87803

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:268494 CAPLUS
DN 128:308398
TI Preparation of hydroxamides as metalloproteinase inhibitors
IN Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PA British Biotech Pharmaceuticals Ltd., UK; Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9817655	A1	19980430	WO 1997-GB2891	19971020
	W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2269283	A1	19980430	CA 1997-2269283	19971020
	AU 9747142	A	19980515	AU 1997-47142	19971020
	AU 713603	B2	19991209		
	GB 2324091	A	19981014	GB 1998-16616	19971020
	GB 2324091	B	20001115		
	EP 934292	A1	19990811	EP 1997-909461	19971020
	EP 934292	B1	20060315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	NZ 334711	A	20001027	NZ 1997-334711	19971020
	JP 2001502348	T	20010220	JP 1998-519112	19971020
	AT 320422	T	20060415	AT 1997-909461	19971020
	PT 1030842	T	20030731	PT 1997-912351	19971113
	ES 2195122	T3	20031201	ES 1997-912351	19971113
	ZA 9710611	A	19980612	ZA 1997-10611	19971125
	US 6022873	A	20000208	US 1998-121033	19980723
PRAI	GB 1996-21814	A	19961019		
	WO 1997-GB2891	W	19971020		
	EP 1997-912351	A	19971113		

OS MARPAT 128:308398
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:410405 CAPLUS
DN 125:86638
TI Imidazopyridine derivatives as dual histamine (H1) and platelet activating factor (PAF) antagonists.
IN Miller, Andrew; Bowles, Stephen Arthur; Ayscough, Andrew Paul; Whittaker, Mark
PA British Biotech Pharmaceuticals Limited, UK
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9605201	A1	19960222	WO 1995-GB1878	19950809
	W: AU, CA, CN, CZ, DE, FI, GB, HU, JP, KR, NO, NZ, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9531863	A	19960307	AU 1995-31863	19950809
	EP 775139	A1	19970528	EP 1995-927872	19950809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5753671	A	19980519	US 1997-776783	19970210
PRAI	GB 1994-16143	A	19940810		
	GB 1995-5808	A	19950322		
	WO 1995-GB1878	W	19950809		

OS MARPAT 125:86638

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1994:107072 CAPLUS
DN 120:107072
TI 4-(1H-2-methylimidazo[4,5-c]pyridinylmethyl)phenylsulfonamide derivatives as antagonists of platelet-activating factor
IN Whitaker, Mark; Bowles, Stephen Arthur; Miller, Andrew
PA British Bio-Technology Ltd., UK
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9316075	A1	19930819	WO 1993-GB273	19930210
	W: AU, CA, FI, JP, KR, NO, NZ, PT, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9334599	A	19930903	AU 1993-34599	19930210
	AU 662208	B2	19950824		
	EP 635018	A1	19950125	EP 1993-903261	19930210
	EP 635018	B1	19991222		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07503954	T	19950427	JP 1993-513899	19930210
	AT 187966	T	20000115	AT 1993-903261	19930210
	ES 2142861	T3	20000501	ES 1993-903261	19930210
	US 5516783	A	19960514	US 1994-284570	19941027
PRAI	GB 1992-2791	A	19920211		
	WO 1993-GB273	A	19930210		

OS MARPAT 120:107072

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:633573 CAPLUS
DN 111:233573
TI Syntheses of Nα-(β-naphthylsulfonylglycyl)argininamides as potential selective synthetic thrombin inhibitors
AU Etemad-Moghadam, Guita; Delebassee, Denis; Maffrand, Jean Pierre; Frehel, Daniel
CS Lab. Chim. Coord., Univ. Paul-Sabatier, Toulouse, 31400, Fr.
SO European Journal of Medicinal Chemistry (1988), 23(6), 577-85
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English
OS CASREACT 111:233573

=> d l4 1-18 ibib hitstr

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:259671 CAPLUS
DOCUMENT NUMBER: 146:297694
TITLE: Biocompatible cyanine fluorescent imaging agents and method of in vivo optical imaging
INVENTOR(S): Rajopadhye, Milind; Groves, Kevin
PATENT ASSIGNEE(S): Visen Medical, Inc., USA
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028163	A1	20070308	WO 2006-US34604	20060901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-714075P P 20050902
IT 928031-27-0P 928031-31-6P 928031-35-0P
RL: DGN (Diagnostic use); IMF (Industrial manufacture); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(production of biocompatible fluorescent imaging agents for in vivo optical imaging)

RN 928031-27-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-26-9
CMF C64 H70 N6 O16 S5

PAGE 1-A



L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



CM 2

CRN 121-44-8
CMF C6 H15 N

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



CM 2

CRN 121-44-8
CMF C6 H15 N

RN 928031-31-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-30-5
CMF C62 H70 N4 O16 S5

PAGE 1-A



RN 928031-35-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-34-9
CMF C61 H68 N4 O15 S5

PAGE 1-A



PAGE 1-B



L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 121-44-8
CMF C6 H15 N

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:610647 CAPLUS
DOCUMENT NUMBER: 145:224314
TITLE: Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: hydroxamic acid analogs
AUTHOR(S): Gupta, S. P.; Kumaran, S.
CORPORATE SOURCE: Department of Chemistry, Birla Institute of Technology and Science, Pilani, 333031, India
SOURCE: Medicinal Chemistry (2006), 2(3), 243-250
CODEN: MCEHAJ; ISSN: 1573-4064
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 206553-57-3 206553-72-2 244296-01-3
244296-09-1 244296-22-8 244296-25-1
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(QSAR studies of hydroxamic acid analogs on matrix metalloproteinase inhibitors)
RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-25-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(1-naphthalenylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:241640 CAPLUS
DOCUMENT NUMBER: 142:463562
TITLE: Synthesis of 3-Arylpiperidines by a Radical 1,4-Aryl Migration
AUTHOR(S): Gheorghe, Alexandru; Quiclet-Sire, Beatrice; Vila, Xavier; Zard, Samir Z.
CORPORATE SOURCE: Laboratoire de Synthese Organique, Departement de Chimie, Ecole Polytechnique, Palaiseau, 91128, Fr.
SOURCE: Organic Letters (2005), 7(8), 1653-1656
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:463562
IT 851461-08-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and radical 1,4-aryl migration reaction of)
RN 851461-08-0 CAPLUS
CN Carbonodithioic acid, S-[1-[[acetyl[(4-bromophenyl)sulfonyl]amino]methyl]-4-oxo-4-(1-piperidinyl)butyl] O-ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:857596 CAPLUS
DOCUMENT NUMBER: 141:350198
TITLE: Heterocyclic (piperazine- and piperidine-containing) benzenesulfonamide derivatives, method for their production, therapeutic compositions, and use thereof for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean-Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087700	A1	20041014	WO 2004-FR723	20040324
WO 2004087700	A8	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
FR 2853648	A1	20041015	FR 2003-4530	20030411
FR 2853648	B1	20060818		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
EP 1606288	A1	20051221	EP 2004-742333	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008689	A	20060328	BR 2004-8689	20040324
JP 2006521333	T	20060921	JP 2006-505749	20040324
US 2006178360	A1	20060810	US 2005-549546	20050914
NO 2005004361	A	20051101	NO 2005-4361	20050920

PRIORITY APPLN. INFO.: FR 2003-3602 A 20030325
FR 2003-4530 A 20030411
WO 2004-FR723 A 20040324

OTHER SOURCE(S): MARPAT 141:350198

IT 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(drug candidate, resolution; preparation of piperazine- and piperidine-containing
benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-09-2 CAPLUS

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxoethoxy]ethyl]benzenesulfonamide 775286-20-9P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide 775286-41-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-57-5P, N-[2-[2-(4-Amino-1-piperidinyl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide 775287-58-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of piperazine- and piperidine-contg. benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-11-6 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 766558-25-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-20-9 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-41-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



IT 766558-14-9P, N-[2-[2-[4-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-14-9 CAPLUS
CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-13-8
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 766558-11-6P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide 766558-25-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxy]acetyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 775287-57-5 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775287-58-6 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)



IT 766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]piperazine bis(trifluoroacetate) 766558-08-1P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N,2,4,6-tetramethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[[2-[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]piperazine bis(trifluoroacetate) 766558-18-3P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]piperazine bis(trifluoroacetate) 766558-20-7P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]piperazine bis(trifluoroacetate) 766558-22-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]piperazine bis(trifluoroacetate) 766558-24-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(dimethylamino)propyl]piperazine bis(trifluoroacetate) 766558-26-3P, 4-Methoxy-N,2,6-trimethyl-N-

[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 766558-28-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 766558-30-9P, 1-(1-Azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1H-1,4-diazepine fumarate 775285-46-6P, N-[2-[2-[4-(3-(1-Azetidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-48-8P, N-[2-[2-[4-(1-Methyl-3-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-54-6P, N-[2-[2-[4-[(1-Methyl-2-imidazolyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-56-8P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-58-0P, N-[2-[2-[4-[3-(Dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-60-4P, N-[2-[2-[4-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-62-6P, N-[2-[2-[4-[3-(1-Pyrrolidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-66-0P, N-[2-[2-[4-(8-Cyclopropyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-68-2P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-72-8P, N-[2-[2-[4-(1-Cyclopropyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-74-0P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-76-2P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-78-4P, N-[2-[2-[4-[1-(1,1-Dimethylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-80-8P, N-[2-[2-[4-[(1-Methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-82-0P, N-[2-[2-[4-[3-(Dimethylamino)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide difumarate 775285-84-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide difumarate 775285-85-3P, N-[2-[2-[4-[2-(1-Methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-87-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)hexahydro-1H-1,4-diazepin-1-yl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-89-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-91-1P, N-[2-[2-[4-[1-(1-Methylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-93-3P, N-[2-[2-[4-[3-(1-Piperidinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-95-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methoxy-N-methylbenzenesulfonamide difumarate 775285-97-7P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-

dichloro-4-methoxy-N-methylbenzenesulfonamide fumarate 775285-99-9P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dichlorobenzenesulfonamide fumarate 775286-01-6P, N-[2-[2-[4-(1,2,2,6,6-Pentamethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis(trifluoroacetate) 775286-03-8P, N-[2-[2-[4-[3-(4-Methyl-1-piperazinyl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-05-0P, N-[2-[2-[4-(8-Ethyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-07-2P, N-[2-[2-[4-[3-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)propyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-09-4P, N-[2-[2-[4-[8-(1-Methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-11-8P, N-[2-[2-[4-[3-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)-3-oxopropyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis(trifluoroacetate) 775286-13-0P, N-[2-[2-[4-[2-(4-Methylhexahydro-1H-1,4-diazepin-1-yl)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifumarate 775286-17-4P, N-[2-[2-[4-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775286-19-6P, N-[2-[2-[4-[2-(Diethylamino)ethyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775286-21-0P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide difumarate 775286-22-1P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide 775286-23-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide difumarate 775286-24-3P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide 775286-25-4P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide difumarate 775286-26-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide 775286-27-6P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide difumarate 775286-28-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-2,3,6-trimethyl-N-methylbenzenesulfonamide 775286-29-8P, 4-Methoxy-N,2,3,6-tetramethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-30-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-31-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-methyl-4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-32-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[3-(1-methyl-4-piperidinyl)propyl]-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide difumarate 775286-34-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775286-35-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-amino-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775286-36-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-amino-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide fumarate 775286-38-9P, N-[2-[2-[4-[2-(Dimethylamino)-1,1-dimethylethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-

trimethylbenzenesulfonamide trifluoroacetate 775286-40-3P, N-[2-[2-[4-[2-(Dimethylamino)-1-hydroxyethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775286-42-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-44-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-48-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-50-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[4-(1-methylethyl)-1-piperazinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-52-7P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-56-1P, N-[2-[2-[4-[2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-58-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-[methyl(1-methylethyl)amino]ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-60-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[methyl(1-methyl-4-piperidinyl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-62-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1-(1-methylethyl)-4-piperidinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-64-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-ethyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-66-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-cyclopropyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-68-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-70-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-azetidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-72-1P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-74-3P, N-[2-[2-[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775286-78-7P, 2,4-Dichloro-N,3-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-80-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(1-azetidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-82-3P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-[2-(dimethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-84-5P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-86-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(1-pyrrolidinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-88-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(4-ethyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775286-92-5P, N-Ethyl-4-methoxy-2,6-dimethyl-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-94-7P, N-Methyl-4-methoxy-2,6-dichloro-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775286-96-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate 775286-98-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(1-

pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-00-8P, N-[2-[2-[4-[2-(Ethylmethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775287-02-0P, N-[2-[2-[4-[2-(Diethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775287-04-2P, 4-Methoxy-N-(1-methylethyl)-2,6-dimethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-06-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-08-6P, N-[2-[2-[4-[(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775287-10-0P, 4-Methoxy-N-[2-[2-[4-[2-(1-methyl-4-piperidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate 775287-12-2P, 4-Methoxy-N-[2-[2-[4-(2-(1-piperidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate 775287-14-4P, 4-Methoxy-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N-methyl-2-(trifluoromethyl)benzenesulfonamide trifluoroacetate 775287-16-6P, 4-Methoxy-N-[2-[2-[4-[2-(1-methyl-4-piperazinyl)-2-oxoethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]-N,2,6-trimethylbenzenesulfonamide fumarate 775287-18-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(dimethylamino)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-20-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(1-azetidinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-22-4P, N,2,4,6-Tetramethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate 775287-24-6P, N-Methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]-2-(trifluoromethyl)benzenesulfonamide trifluoroacetate 775287-26-8P, 4-Methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]-2-(trifluoromethyl)benzenesulfonamide trifluoroacetate 775287-28-0P, N,2,4,6-Tetramethyl-N-[2-[2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate 775287-30-4P, 2,6-Dichloro-4-methoxy-N-methyl-N-[2-[2-[4-(1-methyl-4-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-32-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(dimethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-34-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-cyclopropyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-36-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[4-(1,1-dimethylethyl)-1-piperazinyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-38-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-40-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(4-methyl-1-piperazinyl)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-41-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-morpholinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-42-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-morpholinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-43-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-44-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-45-1P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-piperidinyl]-2-

oxoethoxy]ethyl]benzenesulfonamide 775287-46-2P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-47-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-48-4P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(4-methyl-1-piperazinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-49-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-azetidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-50-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(1-azetidinyl)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-51-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-52-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-(dimethylamino)propyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-54-2P, N-[2-[2-(4,4'-Bipiperidin-1-yl)-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide trifluoroacetate 775287-55-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-56-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[2-(methylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775287-59-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-60-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(methylamino)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-61-1P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775287-62-2P
, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-63-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide 775287-64-4P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(1-piperazinylmethyl)-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide fumarate 775287-66-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-[1-oxo-2-(4-methyl-1-piperazinyl)ethyl]-1-piperidinyl]ethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 775287-67-7P,
4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide dihydrochloride 775287-68-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775288-89-6P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[1,1-dimethyl-2-(diethylamino)ethyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide trifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazine- and piperidine-contg. benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-06-9 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-05-8
CMF C24 H40 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-08-1 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-07-0
CMF C25 H40 N4 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-10-5 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-09-2
CMF C25 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-12-7 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-11-6
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-16-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-15-0
CMF C25 H42 N4 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-18-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-22-9 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-21-8
CMF C26 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-24-1 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-17-2
CMF C24 H40 N4 O6 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-20-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[2-(1-piperidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-19-4
CMF C25 H42 N4 O5 S

PAGE 1-A



L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 766558-23-0
CMF C23 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-26-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-30-9 CAPLUS
CN 1H-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-29-6
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-54-6 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[(1-methyl-1H-imidazol-2-yl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-53-5
CMF C23 H35 N5 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-56-8 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho xy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-55-7
CMF C25 H42 N4 O5 S



CM 2

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 775285-46-6 CAPLUS
CN Piperazine, 1-[3-(1-azetidinyl)propyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-45-5
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-48-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-3-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-47-7
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-58-0 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl]sulfonyl]amino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-57-9
CMF C24 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-60-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-59-1
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-62-6 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-61-5
CMF C26 H44 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-66-0 CAPLUS
CN Piperazine, 1-(8-cyclopropyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-65-9
CMF C28 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-68-2 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho

xy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-67-1
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-72-8 CAPLUS
CN Piperazine, 1-(1-cyclopropyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-71-7
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-74-0 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-73-9
CMF C28 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-76-2 CAPLUS
CN Piperazine, 1-(1-ethyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-75-1
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-78-4 CAPLUS
CN Piperazine, 1-[1-(1,1-dimethylethyl)-4-piperidinyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-77-3
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-80-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(1-methyl-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-79-5
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-85-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(1-methyl-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-79-5
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-87-5 CAPLUS
CN 1H-1,4-Diazepine, hexahydro-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-86-4
CMF C25 H42 N4 O5 S



Double bond geometry as shown.



RN 775285-82-0 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-81-9
CMF C21 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-84-2 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-83-1
CMF C22 H34 Cl2 N4 O5 S



CM 2

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-89-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-88-6
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-91-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-90-0
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-93-3 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-92-2
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-95-5 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-94-4
CMF C22 H34 Cl2 N4 O5 S

CRN 775285-98-8
CMF C23 H34 Cl2 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-01-6 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1,2,2,6,6-pentamethyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-00-5
CMF C28 H48 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-97-7 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-ethyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-96-6
CMF C23 H36 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-99-9 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1



RN 775286-03-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-02-7
CMF C26 H45 N5 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-05-0 CAPLUS
CN Piperazine, 1-(8-ethyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-04-9
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-07-2 CAPLUS
CN Piperazine, 1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-06-1
CMF C27 H47 N5 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-09-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[8-(1-methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-08-3
CMF C28 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-11-8 CAPLUS
CN 1H-1,4-Diazepine, hexahydro-1-[3-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-1-oxopropyl]-4-methyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-10-7
CMF C27 H45 N5 O6 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-13-0 CAPLUS
CN Piperazine, 1-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-12-9
CMF C26 H45 N5 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-17-4 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-16-3
CMF C26 H42 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-19-6 CAPLUS
CN 1-Piperazineethanamine, N,N-diethyl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-18-5
CMF C24 H42 N4 O5 S



L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-21-0 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-20-9
CMF C21 H31 Cl2 F N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-22-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-23-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-26-5 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-27-6 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-26-5
CMF C22 H34 Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-28-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

CM 1

CRN 775286-22-1
CMF C21 H31 Br Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-24-3 CAPLUS
CN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775286-25-4 CAPLUS
CN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-24-3
CMF C21 H31 Cl3 N4 O4 S



L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 775286-29-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-28-7
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-30-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 775286-31-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-methyl-4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 775286-32-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-methyl-4-piperidinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-31-2
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-34-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-38-9 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N,β,β-tetramethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-37-8
CMF C25 H43 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-40-3 CAPLUS
CN 4-Piperidinemethanol, α-[(dimethylamino)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-39-0
CMF C23 H39 N3 O6 S

CM 1

CRN 775286-33-4
CMF C23 H38 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-35-6 CAPLUS
CN Piperazine, 1-(6-amino-3-pyridinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775286-36-7 CAPLUS
CN Piperazine, 1-(6-amino-3-pyridinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-35-6
CMF C23 H33 N5 O5 S





CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775286-42-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-41-4
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-44-7 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 775286-43-6
CMF C25 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-48-1 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-47-0
CMF C25 H41 N3 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-50-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxy]acetyl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-49-2
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-52-7 CAPLUS
CN Piperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho xy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-51-6
CMF C26 H43 N3 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-56-1 CAPLUS
CN Piperidine, 4-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-1-[[2-

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-55-0
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-58-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(1-methylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-57-2
CMF C25 H43 N3 O5 S



L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-64-1 CAPLUS
CN 4,4'-Bipiperidine, 1-ethyl-1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-63-0
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-66-3 CAPLUS
CN 4,4'-Bipiperidine, 1-cyclopropyl-1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-65-2

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-60-7 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-59-4
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-62-9 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-(1-methylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-61-8
CMF C27 H45 N3 O5 S

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C27 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-68-5 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-67-4
CMF C25 H41 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-70-9 CAPLUS
CN Piperidine, 4-[2-(1-azetidinyl)-1,1-dimethylethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-69-6
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-72-1 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-71-0
CMF C26 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-74-3 CAPLUS

RN 775286-80-1 CAPLUS
CN Piperidine, 4-[2-(1-azetidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-79-8
CMF C24 H39 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-82-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-81-2
CMF C21 H33 Cl2 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

CN Piperidine, 4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-73-2
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-78-7 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(2,4-dichloro-3-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-77-6
CMF C23 H35 Cl2 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.





RN 775286-84-5 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-83-4
CMF C23 H35 Cl2 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-86-7 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-pyrrolidinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-85-6
CMF C24 H39 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-88-9 CAPLUS
CN Piperidine, 4-[(4-ethyl-1-piperazinyl)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

oxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-93-6
CMF C23 H36 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-96-9 CAPLUS
CN Piperidine, 4-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-95-8
CMF C28 H47 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

CM 1

CRN 775286-87-8
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-92-5 CAPLUS
CN Piperidine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-91-4
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-94-7 CAPLUS
CN Piperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]eth

RN 775286-98-1 CAPLUS
CN Piperidine, 4-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-97-0
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-00-8 CAPLUS
CN 4-Piperidineethanamine, N-ethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-99-2
CMF C24 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-06-4 CAPLUS
CN Piperidine, 4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1-[[2-[[(4-methoxy-2,6-



RN 775287-02-0 CAPLUS
CN 4-Piperidineethanamine, N,N-diethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-01-9
CMF C25 H43 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-04-2 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-03-1
CMF C27 H45 N3 O5 S

dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-05-3
CMF C27 H45 N3 O6 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-08-6 CAPLUS
CN Piperidine, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-07-5
CMF C26 H44 N4 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-10-0 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-methyl-4-piperidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-09-7
CMF C27 H45 N3 O5 S

PAGE 1-A



PAGE 1-B

OMe

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-12-2 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-11-1
CMF C26 H43 N3 O5 S

PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-16-6 CAPLUS
CN Piperazine, 1-[(1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]acetyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-15-5
CMF C26 H42 N4 O6 S

PAGE 1-A



PAGE 1-B

OMe

CM 2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-14-4 CAPLUS
CN Piperidine, 1-[[2-[[[4-methoxy-2-(trifluoromethyl)phenyl]sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-13-3
CMF C24 H36 F3 N3 O5 S

PAGE 1-A



CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-18-8 CAPLUS
CN 4-Piperidinemethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-17-7
CMF C22 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-20-2 CAPLUS
CN Piperidine, 4-(1-azetidinylmethyl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-19-9
CMF C23 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-22-4 CAPLUS
CN 4,4'-Bipiperidine, 1-methyl-1'-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-21-3
CMF C25 H41 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-24-6 CAPLUS
CN 4,4'-Bipiperidine, 1-methyl-1'-[[2-[methyl[[2-(trifluoromethyl)phenyl]sulfonyl]amino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-23-5
CMF C23 H34 F3 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-26-8 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[[4-methoxy-2-(trifluoromethyl)phenyl]sulfonyl]methylamino]ethoxy]acetyl]-1'-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-25-7
CMF C24 H36 F3 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-28-0 CAPLUS
CN Piperidine, 1-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]ace

tyl]-4-[2-(1-pyrrolidinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-27-9
CMF C25 H41 N3 O4 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-30-4 CAPLUS
CN Piperidine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-29-1
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-32-6 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-31-5
CMF C23 H39 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-34-8 CAPLUS
CN Piperidine, 4-(4-cyclopropyl-1-piperazinyl)-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-33-7
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-36-0 CAPLUS
CN Piperidine, 4-[4-(1,1-dimethylethyl)-1-piperazinyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-35-9
CMF C27 H46 N4 O5 S



PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-41-7 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 775287-42-8 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-morpholinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-41-7
CMF C26 H43 N3 O6 S

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-38-2 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-37-1
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-40-6 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-methyl-1-piperazinyl)ethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-39-3
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-43-9 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 775287-44-0 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-43-9
CMF C26 H43 N3 O5 S

PAGE 1-A



CMF C28 H48 N4 O5 S

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-47-3 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 775287-48-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(4-methyl-1-piperazinyl)propyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-45-1 CAPLUS
CN Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775287-46-2 CAPLUS
CN Piperidine, 4-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-45-1

CRN 775287-47-3
CMF C27 H46 N4 O5 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-49-5 CAPLUS
CN Piperidine, 4-[3-(1-azetidinyl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775287-50-8 CAPLUS
CN Piperidine, 4-[3-(1-azetidinyl)propyl]-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-49-5
CMF C25 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-51-9 CAPLUS
CN 4-Piperidinepropanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 775287-52-0 CAPLUS
CN 4-Piperidinepropanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-51-9
CMF C24 H41 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

CMF C22 H37 N3 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-59-7 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-58-6
CMF C27 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 775287-60-0 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775287-54-2 CAPLUS
CN 4,4'-Bipiperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-53-1
CMF C24 H39 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-55-3 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 775287-56-4 CAPLUS
CN 4-Piperidineethanamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-55-3



RN 775287-61-1 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)



RN 775287-62-2 CAPLUS
CN 4-Piperidinamine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-61-1
CMF C28 H46 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-63-3 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)



RN 775287-64-4 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-piperazinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-63-3
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-66-6 CAPLUS
CN Piperidine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-[(4-methyl-1-piperazinyl)acetyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775287-65-5
CMF C26 H42 N4 O6 S

PAGE 1-A



CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775288-89-6 CAPLUS
CN 4-Piperidineethanamine, N,N-diethyl-1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-β,β-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775288-88-5
CMF C27 H47 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 775288-66-9P, 4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methy lamino]ethoxy]acetyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 775288-67-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-(1-piperazinyl)ethoxy]ethyl]benzenesulfonamide 775288-69-2P, 4-[3-[4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]ac etyl]-1-piperazinyl]propyl]-1-piperidinecarboxylic acid phenylmethyl ester 775288-70-5P, 4-[4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 775288-73-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-oxo-2-[4-(6-nitro-3-pyridinyl)-1-piperazinyl]ethoxy]ethyl]benzenesulfonamide 775288-74-9P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(3-hydroxypropyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775288-75-0P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-[3-[[(4-methylphenyl)sulfonyl]oxy]pro pyl]-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775288-76-1P, 1'-[[2-[[(4-Methoxy-2,6-

PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 775287-67-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 775287-68-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4,4'-bipiperidine-1-carboxylic acid 1,1-dimethylethyl ester 775288-77-2P, [2-[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acet yl]-4-piperidinyl]ethyl](methyl)carbamic acid 1,1-dimethylethyl ester 775288-78-3P, [1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]carbamic acid 1,1-dimethylethyl ester 775288-79-4P, [1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl](methyl)carbamic acid 1,1-dimethylethyl ester 775288-82-9P, 4-[[1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl]-1-piperazinecarboxylic acid phenylmethyl ester 775288-83-0P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinecarboxylic acid ethyl ester 775288-84-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinecarboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of piperazine- and piperidine-contg. benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 775288-66-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-67-0 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775288-69-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-70-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-73-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(6-nitro-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 775288-74-9 CAPLUS
CN 4-Piperidinepropanol, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t

RN 775288-78-3 CAPLUS
CN Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-79-4 CAPLUS
CN Carbamic acid, [1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-82-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 775288-75-0 CAPLUS
CN 4-Piperidinepropanol, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-76-1 CAPLUS
CN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 775288-77-2 CAPLUS
CN Carbamic acid, [2-[1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-piperidinyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 775288-83-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 775288-84-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:800854 CAPLUS
DOCUMENT NUMBER: 141:314016
TITLE: Preparation of benzenesulfonamides as Bradykinin B1 receptors antagonists for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: Fr. Demande, 27 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
WO 2004087700	A1	20041014	WO 2004-FR723	20040324
WO 2004087700	A8	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1606288	A1	20051221	EP 2004-742333	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008689	A	20060328	BR 2004-8689	20040324
CN 1764661	A	20060426	CN 2004-80007762	20040324
JP 2006521333	T	20060921	JP 2006-505749	20040324
NO 2005004361	A	20051101	NO 2005-4361	20050920

PRIORITY APPLN. INFO.:
FR 2003-3602 A 20030325
FR 2003-4530 A 20030411
WO 2004-FR723 A 20040324

OTHER SOURCE(S): MARPAT 141:314016

IT 766558-09-2P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-09-2 CAPLUS

CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

]-4-[3-(dimethylamino)propyl]piperazine bistrifluoroacetate 766558-26-3P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bistrifluoroacetate 766558-28-5P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 766558-30-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Bradykinin B1 receptor antagonist; prepn. of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-06-9 CAPLUS

CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-05-8
CMF C24 H40 N4 O5 S

PAGE 1-A



L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 766558-11-6P, N-[2-[2-[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 766558-11-6 CAPLUS

CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 766558-06-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(1-pyrrolidinyl)ethyl]piperazine bistrifluoroacetate 766558-08-1P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-N-methyl-2,4,6-trimethylbenzenesulfonamide bistrifluoroacetate 766558-10-5P, N-[2-[2-[4-(1-Azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide difumarate 766558-12-7P, N-[2-[2-[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-14-9P, N-[2-[2-[4-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide fumarate 766558-16-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]piperazine bistrifluoroacetate 766558-18-3P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]piperazine bistrifluoroacetate 766558-20-7P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]piperazine bistrifluoroacetate 766558-22-9P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]piperazine bistrifluoroacetate 766558-24-1P, 1-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino]ethoxy]acetyl

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-08-1 CAPLUS

CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[methyl[(2,4,6-trimethylphenyl)sulfonyl]amino]ethoxy]acetyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-07-0
CMF C25 H40 N4 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-10-5 CAPLUS
CN Piperazine, 1-(1-azabicyclo[2.2.2]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-09-2
CMF C25 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-12-7 CAPLUS
CN Piperazine, 1-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-11-6
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-14-9 CAPLUS
CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-13-8
CMF C25 H40 N4 O5 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-16-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-pyrrolidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-15-0
CMF C25 H42 N4 O5 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-18-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(4-morpholinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-17-2
CMF C24 H40 N4 O6 S

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-20-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[2-(1-piperidinyl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-19-4
CMF C25 H42 N4 O5 S

PAGE 1-A



PAGE 1-B

—OMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-22-9 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[3-(1-piperidinyl)propyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-21-8
CMF C26 H44 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 766558-30-9 CAPLUS
CN 1H-1,4-Diazepine, 1-(1-azabicyclo[2.2.2]oct-3-yl)hexahydro-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-29-6
CMF C26 H42 N4 O5 S

RN 766558-24-1 CAPLUS
CN 1-Piperazinepropanamine, 4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-N,N-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-23-0
CMF C23 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-26-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 766558-13-8P, N-[2-[2-[4-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-methyl-2,6-dimethylbenzenesulfonamide
RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)
RN 766558-13-8 CAPLUS
CN Piperazine, 1-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:349769 CAPLUS
DOCUMENT NUMBER: 141:71820
TITLE: Synthesis of Cyclic Peptidosulfonamides by Ring-Closing Metathesis
AUTHOR(S): Brouwer, Arwin J.; Liskamp, Rob M. J.
CORPORATE SOURCE: Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NL-3508 TB, Neth.
SOURCE: Journal of Organic Chemistry (2004), 69(11), 3662-3668
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:71820
IT 710300-63-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic peptidosulfonamides by ring-closing metathesis)
RN 710300-63-3 CAPLUS
CN Piperidine, 1-[(2S)-4-methyl-2-[[[(2S)-3-methyl-2-[[(2-nitrophenyl)sulfonyl]-2-propenylamino]butyl]sulfonyl]-2-propenylamino]-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:485895 CAPLUS
DOCUMENT NUMBER: 139:223711
TITLE: Novel inhibitors of procollagen C-Proteinase. Part 2: glutamic acid hydroxamates
AUTHOR(S): Robinson, L. A.; Wilson, D. M.; Delaet, N. G. J.; Bradley, E. K.; Dankwardt, S. M.; Campbell, J. A.; Martin, R. L.; Van Wart, H. E.; Walker, K. A. M.; Sullivan, R. W.
CORPORATE SOURCE: CombiChem Inc., San Diego, CA, 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2381-2384
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:223711
IT 279254-86-3P 279254-91-0P 279254-97-6P
279255-03-7P 279255-56-0P 279255-58-2P
591766-09-5P 591766-10-8P 591766-11-9P
591766-12-0P 591766-13-1P 591766-14-2P
591766-15-3P 591766-16-4P 591766-17-5P
591766-18-6P 591766-19-7P 591766-20-0P
591766-21-1P 591766-22-2P 591766-23-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure-activity relationship of glutamic acid hydroxamates as novel inhibitors of procollagen C-Proteinase)
RN 279254-86-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-91-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 279254-97-6 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-03-7 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 279255-56-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-benzoyl-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-58-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-(2-furanylcarbonyl)-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-09-5 CAPLUS
CN 1-Piperidinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-10-8 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-11-9 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-methyl-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-12-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-13-1 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-14-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-

methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-15-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-16-4 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(3-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-17-5 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-

methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(4-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-18-6 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-19-7 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-(methylsulfonyl)-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-20-0 CAPLUS

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-21-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-22-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-[[(4-methoxyphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 591766-23-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-[[(3-methoxyphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:441768 CAPLUS
DOCUMENT NUMBER: 133:74324
TITLE: Preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase.
INVENTOR(S): Billedeau, Roland Joseph; Broka, Chris Allen; Campbell, Jeffrey Allen; Chen, Jian Jeffrey; Dankwardt, Sharon Marie; Delaet, Nancy; Robinson, Leslie Ann; Walker, Keith Adrian Murray
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037436	A1	20000629	WO 1999-EP9920	19991214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355902	A1	20000629	CA 1999-2355902	19991214
BR 9916504	A	20010911	BR 1999-16504	19991214
EP 1149072	A1	20011031	EP 1999-963530	19991214
EP 1149072	B1	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101868	T2	20011121	TR 2001-200101868	19991214
HU 200104658	A2	20020629	HU 2001-4658	19991214
JP 2002533322	T	20021008	JP 2000-589508	19991214
AU 769319	B2	20040122	AU 2000-19792	19991214
NZ 512292	A	20040326	NZ 1999-512292	19991214
AT 270271	T	20040715	AT 1999-963530	19991214
RU 2232751	C2	20040720	RU 2001-119461	19991214
US 6492394	B1	20021210	US 1999-469660	19991222
HR 2001000443	A1	20020630	HR 2001-443	20010614
ZA 2001005014	A	20020919	ZA 2001-5014	20010619
MX 2001PA06328	A	20010910	MX 2001-PA6328	20010620
IN 2001CN00859	A	20050304	IN 2001-CN859	20010620
NO 2001003100	A	20010821	NO 2001-3100	20010621
US 2003199520	A1	20031023	US 2002-267292	20021009
US 6844366	B2	20050118		
US 2003216405	A1	20031120	US 2002-267727	20021009
US 6787559	B2	20040907		

PRIORITY APPLN. INFO.:

US 1998-113311P	P	19981222
US 1999-147053P	P	19990803
US 1999-164138P	P	19991108
WO 1999-EP9920	W	19991214
US 1999-469660	A3	19991222

OTHER SOURCE(S): MARPAT 133:74324
IT 279254-86-3P 279254-88-5P 279254-89-6P 279254-90-9P 279254-91-0P 279254-92-1P 279254-97-6P 279254-98-7P 279255-01-5P 279255-02-6P 279255-03-7P 279255-15-1P

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
279255-16-2P 279255-21-9P 279255-25-3P 279255-56-0P 279255-58-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase)
RN 279254-86-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-88-5 CAPLUS
CN 1-Piperazinepentanamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][(4-methyl-3-nitrophenyl)methyl]amino]-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-89-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-90-9 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[[(3-fluorophenyl)methyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-91-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-98-7 CAPLUS
CN 1-Piperazinepentanamide, α-[[(3-fluorophenyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-01-5 CAPLUS
CN 1-Piperazinepentanamide, α-[[(3-fluorophenyl)methyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-92-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[[(3-fluorophenyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-97-6 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-02-6 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[[(3-fluorophenyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-03-7 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-15-1 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-[[(4-methylphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-16-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-[[(3-methoxyphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-56-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-benzoyl-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-58-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-(2-furanylcarbonyl)-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-21-9 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenoxyacetyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-25-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-(methylsulfonyl)-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:96004 CAPLUS
DOCUMENT NUMBER: 132:151682
TITLE: Preparation of sulfonylaminoalkanediamides and related compounds as matrix metalloproteinase inhibitors.
INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK
SOURCE: U.S., 32 pp., Cont.-in-part of Ser. No. Wo97GB-9702891.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6022873	A	20000208	US 1998-121033	19980723
WO 9817655	A1	19980430	WO 1997-GB2891	19971020
W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PT 1030842	T	20030731	PT 1997-912351	19971113
ES 2195122	T3	20031201	ES 1997-912351	19971113
PRIORITY APPLN. INFO.:			GB 1996-21814 A	19961019
			WO 1997-GB2891 A2	19971020
			EP 1997-912351 A	19971113

OTHER SOURCE(S): MARPAT 132:151682
IT 206553-54-0P 206553-55-1P 206553-57-3P
206553-63-1P 206553-64-2P 206553-66-4P
206553-67-5P 206553-68-6P 206553-70-0P
206553-72-2P 206553-74-4P 206553-75-5P
206553-76-6P 206553-77-7P 206553-78-8P
206553-81-3P 244296-01-3P 244296-06-8P
244296-07-9P 244296-09-1P 244296-10-4P
244296-16-0P 244296-17-1P 244296-22-8P
244296-23-9P 244296-25-1P 244296-26-2P
244296-27-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminoalkanediamides and related compds. as matrix metalloproteinase inhibitors)
RN 206553-54-0 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[3-[[(4-methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 206553-66-4 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chloro-2,5-dimethylphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-67-5 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(2,5-dimethoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-68-6 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-β-(2-methylpropyl)-α-[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 206553-55-1 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[2-[[(4-methoxyphenyl)sulfonyl]methylamino]ethyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-63-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-butoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-64-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-70-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-74-4 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl(2-naphthalenylsulfonyl)amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-75-5 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(3,4-dichlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-76-6 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(5-chloro-2-methoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-77-7 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-78-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[1,1'-biphenyl]-4-ylsulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-81-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[(methyl[(4-methylphenyl)sulfonyl]amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-06-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-07-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-10-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-09-1
CMF C29 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244296-16-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-

naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-17-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-16-0
CMF C28 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 244296-26-2 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[(5-isoquinolinylsulfonyl)methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-27-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[6-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 206553-91-5P 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonylaminoalkanediamides and related compds. as matrix metalloproteinase inhibitors)

RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-23-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-25-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(1-naphthalenylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 206553-91-5 CAPLUS
CN 1-Piperidinebutanoic acid, α-[3-[[(4-methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, 1,1-dimethylethyl ester, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-96-0 CAPLUS
CN 1-Piperidinebutanoic acid, α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:662331 CAPLUS
DOCUMENT NUMBER: 132:30315
TITLE: The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors
AUTHOR(S): Martin, Fionna M.; Beckett, R. Paul; Bellamy, Claire L.; Courtney, Paul F.; Davies, Stephen J.; Drummond, Alan H.; Dodd, Rory; Pratt, Lisa M.; Patel, Sanjay R.; Ricketts, Michelle L.; Todd, Richard S.; Tuffnell, Andrew R.; Ward, John W. S.; Whittaker, Mark
CORPORATE SOURCE: British Biotech Pharmaceuticals Limited, Oxford, OX4 5LY, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(19), 2887-2892
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 206553-57-3P 206553-72-2P 244296-01-3P
244296-09-1P 244296-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biol. evaluation of non-peptidic matrix metalloproteinase inhibitors in relation to oral bioavailability)
RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:626184 CAPLUS
DOCUMENT NUMBER: 131:242793
TITLE: Preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors
INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9948881	A1	19990930	WO 1998-GB914	19980325
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9868435	A	19991018	AU 1998-68435	19980325
EP 1066273	A1	20010110	EP 1998-913910	19980325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003522723	T	20030729	JP 2000-537864	19980325

PRIORITY APPLN. INFO.: WO 1998-GB914 A 19980325
IT 244296-01-3P 244296-06-8P 244296-07-9P
244296-09-1P 244296-10-4P 244296-16-0P
244296-17-1P 244296-22-8P 244296-23-9P
244296-25-1P 244296-26-2P 244296-28-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acids and carboxylic acids as metalloproteinase
inhibitors)
RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-06-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-07-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-10-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

RN 244296-17-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-16-0
CMF C28 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CM 1

CRN 244296-09-1
CMF C29 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244296-16-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 244296-23-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-25-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(1-naphthalenylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-26-2 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[(5-isoquinolinylsulfonyl)methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-28-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[6-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-27-3
CMF C29 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxamic acids and carboxylic acids as metalloproteinase

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
inhibitors)
RN 206553-96-0 CAPLUS
CN 1-Piperidinebutanoic acid, α-[[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 206553-57-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors)
RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:460409 CAPLUS
DOCUMENT NUMBER: 131:87805
TITLE: Preparation of amprenavir prodrugs as HIV protease inhibitors
INVENTOR(S): Tung, Roger D.; Hale, Michael R.; Baker, Christopher T.; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Wieczyslaw; Spaltenstein, Andrew
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933815	A1	19990708	WO 1998-US4595	19980309
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6436989	B1	20020820	US 1997-998050	19971224
AU 9865466	A	19990719	AU 1998-65466	19980309
AU 755087	B2	20021205		
TR 200002615	T2	20010122	TR 2000-200002615	19980309
BR 9814480	A	20010925	BR 1998-14480	19980309
EE 200000385	A	20011217	EE 2000-385	19980309
EE 4466	B1	20050415		
HU 200101831	A2	20020429	HU 2001-1831	19980309
HU 200101831	A3	20020828		
AP 1172	A	20030630	AP 2000-1850	19980309
W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
NZ 505776	A	20030630	NZ 1998-505776	19980309
CA 2231700	C	19990624	CA 1998-2231700	19980310
CA 2231700	A1	19990624		
JP 11209337	A	19990803	JP 1998-58705	19980310
JP 3736964	B2	20060118		
EP 933372	A1	19990804	EP 1998-104292	19980310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TW 486474	B	20020511	TW 1998-87121460	19981222
ZA 9811830	A	20000623	ZA 1998-11830	19981223
IN 1998CA02210	A	20051014	IN 1998-CA2210	19981223
NO 2000003304	A	20000821	NO 2000-3304	20000623
MX 2000PA06315	A	20010219	MX 2000-PA6315	20000623
US 6559137	B1	20030506	US 2000-602494	20000623
BG 104631	A	20010228	BG 2000-104631	20000724
BG 64869	B1	20060731		
US 2003207871	A1	20031106	US 2003-370171	20030219
US 6838474	B2	20050104		
US 2005148548	A1	20050707	US 2004-958223	20041004
JP 2005350478	A	20051222	JP 2005-205007	20050713

PRIORITY APPLN. INFO.:

US 1997-998050	A2	19971224
WO 1998-US4595	W	19980309
JP 1998-58705	A3	19980310
US 2000-602494	A3	20000623
US 2003-370171	A3	20030219

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

OTHER SOURCE(S): MARPAT 131:87805
IT 229495-38-9P 229495-43-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amprenavir prodrugs as HIV protease inhibitors)
RN 229495-38-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-methyl-, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]methyl]-3-phenyl-2-[[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]amino]propyl ester, trifluoroacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 229495-37-8
CMF C31 H45 N5 O7 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 229495-43-6 CAPLUS
CN 1-Piperazinecarboxylic acid, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]methyl]-3-phenyl-2-[[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]amino]propyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229495-42-5
CMF C30 H43 N5 O7 S

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:460393 CAPLUS
DOCUMENT NUMBER: 131:87804
TITLE: Preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
INVENTOR(S): Hale, Michael R.; Tung, Roger D.; Baker, Christopher T.; Spaltenstein, Andrew; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933793	A2	19990708	WO 1998-US27424	19981223
WO 9933793	A3	19990910		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2316218	A1	19990708	CA 1998-2316218	19981223
AU 9920925	A	19990719	AU 1999-20925	19981223
BR 9814484	A	20001010	BR 1998-14484	19981223
EP 1042280	A2	20001011	EP 1998-965466	19981223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002402	T2	20010122	TR 2000-200002402	19981223
EE 200000386	A	20011217	EE 2000-386	19981223
JP 2001527062	T	20011225	JP 2000-526477	19981223
HU 200101598	A2	20020429	HU 2001-1598	19981223
HU 200101598	A3	20020828		
CN 1110492	B	20030604	CN 1998-813313	19981223
MX 2000PA06316	A	20010219	MX 2000-PA6316	20000623
NO 2000003332	A	20000818	NO 2000-3332	20000626
IN 2000KN00131	A	20050311	IN 2000-KN131	20000713
HR 2000000499	A1	20010430	HR 2000-499	20000724
US 2002082249	A1	20020627	US 2001-998617	20011130
US 2003144217	A1	20030731	US 2002-226430	20020821

PRIORITY APPLN. INFO.:

US 1997-68869P	P	19971224
WO 1998-US27424	W	19981223
US 2000-602984	A1	20000623
US 2001-998617	B1	20011130

OTHER SOURCE(S): MARPAT 131:87804
IT 229495-37-8P 229495-42-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors)
RN 229495-37-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-methyl-, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]methyl]-3-phenyl-2-[[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]amino]propyl ester (9CI) (CA INDEX

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
NAME)

Absolute stereochemistry.



RN 229495-42-5 CAPLUS
CN 1-Piperazinecarboxylic acid, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]methyl]-3-phenyl-2-[[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:460392 CAPLUS
DOCUMENT NUMBER: 131:87803
TITLE: Preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors.
INVENTOR(S): Hale, Michael R.; Tung, Roger D.; Baker, Christopher T.; Spaltenstein, Andrew; Furfine, Eric Steven; Kaldor, Istvan; Kazmierski, Wieslaw Mieczyslaw
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933792	A2	19990708	WO 1998-US27403	19981223
WO 9933792	A3	19990916		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9920102	A	19990719	AU 1999-20102	19981223

PRIORITY APPLN. INFO.:

US 1997-68806P	P	19971224
WO 1998-US27403	W	19981223

OTHER SOURCE(S): MARPAT 131:87803
IT 229495-37-8P 229495-42-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-diacylamino-2-acyloxypropanes as prodrugs of aspartyl protease inhibitors)
RN 229495-37-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-methyl-, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]methyl]-3-phenyl-2-[[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 229495-42-5 CAPLUS
CN 1-Piperazinecarboxylic acid, (1R,2S)-1-[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]methyl]-3-phenyl-2-[[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:268494 CAPLUS
DOCUMENT NUMBER: 128:308398
TITLE: Preparation of hydroxamides as metalloproteinase inhibitors
INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK; Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817655	A1	19980430	WO 1997-GB2891	19971020
W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2269283	A1	19980430	CA 1997-2269283	19971020
AU 9747142	A	19980515	AU 1997-47142	19971020
AU 713603	B2	19991209		
GB 2324091	A	19981014	GB 1998-16616	19971020
GB 2324091	B	20001115		
EP 934292	A1	19990811	EP 1997-909461	19971020
EP 934292	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
NZ 334711	A	20001027	NZ 1997-334711	19971020
JP 2001502348	T	20010220	JP 1998-519112	19971020
AT 320422	T	20060415	AT 1997-909461	19971020
PT 1030842	T	20030731	PT 1997-912351	19971113
ES 2195122	T3	20031201	ES 1997-912351	19971113
ZA 9710611	A	19980612	ZA 1997-10611	19971125
US 6022873	A	20000208	US 1998-121033	19980723

PRIORITY APPLN. INFO.:
GB 1996-21814 A 19961019
WO 1997-GB2891 W 19971020
EP 1997-912351 A 19971113

OTHER SOURCE(S): MARPAT 128:308398
IT 206553-54-0P 206553-55-1P 206553-57-3P
206553-63-1P 206553-64-2P 206553-66-4P
206553-67-5P 206553-68-6P 206553-70-0P
206553-72-2P 206553-74-4P 206553-75-5P
206553-76-6P 206553-77-7P 206553-78-8P
206553-81-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamides as metalloproteinase inhibitors)
RN 206553-54-0 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[3-[[(4-methoxyphenyl]sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-55-1 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[2-[[(4-methoxyphenyl]sulfonyl]methylamino]ethyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl]sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-63-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-butoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-64-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-66-4 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chloro-2,5-dimethylphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-67-5 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(2,5-dimethoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-68-6 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-β-(2-methylpropyl)-α-[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-70-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 206553-77-7 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-78-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(1,1'-biphenyl]-4-ylsulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-81-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl[(4-methylphenyl]sulfonyl]amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-74-4 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl(2-naphthalenylsulfonyl)amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-75-5 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(3,4-dichlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-76-6 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(5-chloro-2-methoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)



IT 206553-91-5P 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxamides as metalloproteinase inhibitors)

RN 206553-91-5 CAPLUS
CN 1-Piperidinebutanoic acid, α-[3-[[(4-methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, 1,1-dimethylethyl ester, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-96-0 CAPLUS
CN 1-Piperidinebutanoic acid, α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:410405 CAPLUS
DOCUMENT NUMBER: 125:86638
TITLE: Imidazopyridine derivatives as dual histamine (H1) and platelet activating factor (PAF) antagonists.
INVENTOR(S): Miller, Andrew; Bowles, Stephen Arthur; Ayscough, Andrew Paul; Whittaker, Mark
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9605201	A1	19960222	WO 1995-GB1878	19950809
W: AU, CA, CN, CZ, DE, FI, GB, HU, JP, KR, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9531863	A	19960307	AU 1995-31863	19950809
EP 775139	A1	19970528	EP 1995-927872	19950809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5753671	A	19980519	US 1997-776783	19970210
PRIORITY APPLN. INFO.:			GB 1994-16143 A	19940810
			GB 1995-5808 A	19950322
			WO 1995-GB1878 W	19950809

OTHER SOURCE(S): MARPAT 125:86638
IT 178416-74-5P 178416-85-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as dual antihistamines and PAF antagonists)
RN 178416-74-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, 4-methyl-2-[methyl[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]amino]pentyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178416-85-8 CAPLUS

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Piperidine, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-[[[4-methyl-2-[methyl[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]amino]pentyl]oxy)acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:107072 CAPLUS
DOCUMENT NUMBER: 120:107072
TITLE: 4-(1H-2-methylimidazo[4,5-c]pyridinylmethyl)phenylsulfonamide derivatives as antagonists of platelet-activating factor
INVENTOR(S): Whitaker, Mark; Bowles, Stephen Arthur; Miller, Andrew
PATENT ASSIGNEE(S): British Bio-Technology Ltd., UK
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316075	A1	19930819	WO 1993-GB273	19930210
W: AU, CA, FI, JP, KR, NO, NZ, PT, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9334599	A	19930903	AU 1993-34599	19930210
AU 662208	B2	19950824		
EP 635018	A1	19950125	EP 1993-903261	19930210
EP 635018	B1	19991222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07503954	T	19950427	JP 1993-513899	19930210
AT 187966	T	20000115	AT 1993-903261	19930210
ES 2142861	T3	20000501	ES 1993-903261	19930210
US 5516783	A	19960514	US 1994-284570	19941027
PRIORITY APPLN. INFO.:			GB 1992-2791 A	19920211
			WO 1993-GB273 A	19930210

OTHER SOURCE(S): MARPAT 120:107072
IT 151916-56-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as platelet-activating factor antagonist)
RN 151916-56-2 CAPLUS
CN 1,4-Piperazinedicarboxylic acid, ethyl 4-methyl-2-[methyl[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]amino]pentyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:633573 CAPLUS
DOCUMENT NUMBER: 111:233573
TITLE: Syntheses of Nα-(β-naphthylsulfonylglycyl)arginiamides as potential selective synthetic thrombin inhibitors
AUTHOR(S): Etemad-Moghadam, Guita; Delebassee, Denis; Maffrand, Jean Pierre; Frehel, Daniel
CORPORATE SOURCE: Lab. Chim. Coord., Univ. Paul-Sabatier, Toulouse, 31400, Fr.
SOURCE: European Journal of Medicinal Chemistry (1988), 23(6), 577-85
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:233573
IT 123760-52-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and catalytic hydrogenolysis of)
RN 123760-52-1 CAPLUS
CN Acetamide, N-[(1S)-4-[[imino(nitroamino)methyl]amino]-1-(1-piperidinylcarbonyl)butyl]-2-[methyl(2-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 123760-42-9P 123781-80-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and thrombin inhibitory activity of)
RN 123760-42-9 CAPLUS
CN Acetamide, N-[4-[(aminoiminomethyl)amino]-1-(1-piperidinylcarbonyl)butyl]-2-[methyl(2-naphthalenylsulfonyl)amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123781-80-6 CAPLUS

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Acetamide, N-[4-[(aminoiminomethyl)amino]-1-(1-piperidinylcarbonyl)butyl]-2-[methyl(2-naphthalenylsulfonyl)amino]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    95.80     269.01

STN INTERNATIONAL LOGOFF AT 10:09:44 ON 10 JUL 2007


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS  3  MAR 16   CASREACT coverage extended
 NEWS  4  MAR 20   MARPAT now updated daily
 NEWS  5  MAR 22   LWPI reloaded
 NEWS  6  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS  7  APR 02   JICST-EPLUS removed from database clusters and STN
 NEWS  8  APR 30   GENBANK reloaded and enhanced with Genome Project ID field
 NEWS  9  APR 30   CHEMCATS enhanced with 1.2 million new records
 NEWS 10  APR 30   CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 11  APR 30   INPADOC replaced by INPADOCDB on STN
 NEWS 12  MAY 01   New CAS web site launched
 NEWS 13  MAY 08   CA/CAplus Indian patent publication number format defined
 NEWS 14  MAY 14   RDISCLOSURE on STN Easy enhanced with new search and display
                   fields
 NEWS 15  MAY 21   BIOSIS reloaded and enhanced with archival data
 NEWS 16  MAY 21   TOXCENTER enhanced with BIOSIS reload
 NEWS 17  MAY 21   CA/CAplus enhanced with additional kind codes for German
                   patents
 NEWS 18  MAY 22   CA/CAplus enhanced with IPC reclassification in Japanese
                   patents
 NEWS 19  JUN 27   CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 20  JUN 29   STN Viewer now available
 NEWS 21  JUN 29   STN Express, Version 8.2, now available
 NEWS 22  JUL 02   LEMBASE coverage updated
 NEWS 23  JUL 02   LMEDLINE coverage updated
 NEWS 24  JUL 02   SCISEARCH enhanced with complete author names
 NEWS 25  JUL 02   CHEMCATS accession numbers revised
 NEWS 26  JUL 02   CA/CAplus enhanced with utility model patents from China

 NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
```

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:52:02 ON 10 JUL 2007

=> file registry
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:52:08 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 JUL 2007  HIGHEST RN 941818-42-4
DICTIONARY FILE UPDATES:   9 JUL 2007  HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10549546c.str
```



chain nodes :
7 8 10 11 12 19 20 21 22 29 30 31
ring nodes :
1 2 3 4 5 6 9 14 15 16 17 18 23 24 25 26 27 28
chain bonds :
6-7 7-12 7-11 7-30 8-10 8-9 8-19 16-23 19-20 20-21 21-22 22-30 26-29
30-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-14 9-18 14-15 15-16 16-17 17-18 23-24 23-28
24-25 25-26 26-27 27-28
exact/norm bonds :
6-7 7-12 7-11 7-30 8-10 8-9 9-14 9-18 14-15 15-16 16-17 16-23 17-18
19-20 20-21 22-30 23-24 23-28 24-25 25-26 26-27 26-29 27-28 30-31
exact bonds :
8-19 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:CLASS 30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 10:52:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       11 TO ITERATE

100.0% PROCESSED       11 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           22 TO      418
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1

=> d scan
```

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI)
MF C22 H34 Cl2 N4 O5 S . 2 C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho xy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI)
MF C27 H44 N4 O5 S . 2 C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI)
MF C21 H31 Cl3 N4 O4 S . 2 C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI)
MF C22 H34 Cl2 N4 O5 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate (1:1) (9CI)
MF C27 H44 N4 O5 S . C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



ALL ANSWERS HAVE BEEN SCANNED

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         1.80       2.01

FILE 'CAPLUS' ENTERED AT 10:54:37 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 Jul 2007  VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007  (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.47       2.48

FILE 'REGISTRY' ENTERED AT 10:54:43 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     9 JUL 2007  HIGHEST RN 941818-42-4
DICTIONARY FILE UPDATES:    9 JUL 2007  HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
```

```
=> s l2 full
FULL SEARCH INITIATED 10:54:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      135 TO ITERATE

100.0% PROCESSED      135 ITERATIONS                                45 ANSWERS
SEARCH TIME: 00.00.01

L3            45 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     174.58

FILE 'CAPLUS' ENTERED AT 10:54:55 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 10 Jul 2007  VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007  (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            2 L3

=> d l4 1-2 ibib abs hitstr
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857596 CAPLUS
DOCUMENT NUMBER: 141:350198
TITLE: Heterocyclic (piperazine- and piperidine-containing) benzenesulfonamide derivatives, method for their production, therapeutic compositions, and use thereof for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean-Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087700	A1	20041014	WO 2004-FR723	20040324
WO 2004087700	A8	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
FR 2853648	A1	20041015	FR 2003-4530	20030411
FR 2853648	B1	20060818		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
EP 1606288	A1	20051221	EP 2004-742333	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008689	A	20060328	BR 2004-8689	20040324
JP 2006521333	T	20060921	JP 2006-505749	20040324
US 2006178360	A1	20060810	US 2005-549546	20050914
NO 2005004361	A	20051101	NO 2005-4361	20050920

PRIORITY APPLN. INFO.: FR 2003-3602 A 20030325
FR 2003-4530 A 20030411
WO 2004-FR723 A 20040324

OTHER SOURCE(S): MARPAT 141:350198
GI



I



II

AB The invention relates to novel heterocyclic benzenesulfonamide compds. I, a method for their preparation, and their therapeutic use and compns. [wherein: R1, R2, R3, R4 = H, halo, alkyl, alkoxy, CF3, or OCF3; Ra = alkyl; Y = saturated C2-5 alkylene optionally interrupted by O, unsatd. C2-4 alkylene, CH2CONHCH2; X = CH or N; p = 2 or 3; A = bond, NH, NMe, (un)branched C1-5 alkylene optionally bearing OH or an oxo group; provided that A and X together ≠ N; B = N-containing heterocycle or an amine group optionally substituted by 1 or 2 C1-4 alkyl groups; including salts with acids]. The compds. are useful as analgesics and antiinflammatories, particularly for severe pain. Approx. 150 compds. were prepared For instance, 2,6-dimethyl-4-methoxybenzenesulfonyl chloride was amidated with 2-(methylamino)ethanol, (100%), followed by etherification of the free alc. with tert-Bu bromoacetate (94%), deprotection of the tert-Bu ester with TFA (95%), and amidation of the resulting acid with 1-[2-(1-pyrrolidinyl)ethyl]piperazine using a resin-bound diimide reagent and HOAT (13%), to give invention compound II, isolated as the bis(trifluoroacetate). In a formaldehyde-based biphasic pain response test in mice, one compound gave 43% inhibition of 2nd-phase pain at 3 mg/kg orally, and another gave 40% inhibition at 1 mg/kg orally. In a bradykinin B1 receptor assay using human umbilical cord, compds. I had pKB values of 7.5 to 9.2.

IT 766558-25-2P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide 775286-20-9P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-25-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 775286-20-9 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



IT 766558-26-3P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bis(trifluoroacetate) 766558-28-5P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate 775285-56-8P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-60-4P, N-[2-[2-[4-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-68-2P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-ethyl-2,6-dimethylbenzenesulfonamide difumarate 775285-74-0P, N-[2-[2-[4-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-76-2P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-78-4P, N-[2-[2-[4-[1-(1,1-Dimethylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775285-84-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide difumarate 775285-89-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N-(1-methylethyl)-2,6-dimethylbenzenesulfonamide difumarate 775285-91-1P, N-[2-[2-[4-[1-(1-Methylethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide fumarate 775285-95-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methoxy-N-methylbenzenesulfonamide difumarate 775285-97-7P, N-[2-[2-[4-(1-Ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-methoxy-N-methylbenzenesulfonamide fumarate 775286-01-6P, N-[2-[2-[4-(1,2,2,6,6-Pentamethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide bis(trifluoroacetate) 775286-05-0P, N-[2-[2-[4-(8-Ethyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-09-4P, N-[2-[2-[4-[8-(1-Methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

2-oxoethoxy]ethyl]-4-methoxy-N,2,6-trimethylbenzenesulfonamide difumarate 775286-21-0P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,6-dichloro-4-fluoro-N-methylbenzenesulfonamide difumarate 775286-22-1P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide 775286-23-2P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-bromo-2,6-dichloro-N-methylbenzenesulfonamide difumarate 775286-24-3P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide 775286-25-4P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4,6-trichloro-N-methylbenzenesulfonamide difumarate 775286-26-5P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide 775286-27-6P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-2,4-dichloro-6-methyl-N-methylbenzenesulfonamide difumarate 775286-28-7P, N-[2-[2-[4-(1-Methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]-4-methoxy-2,3,6-trimethyl-N-methylbenzenesulfonamide 775286-29-8P, 4-Methoxy-N,2,3,6-tetramethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate 775287-67-7P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide dihydrochloride 775287-68-8P, 4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide difumarate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazine- and piperidine-contg. benzenesulfonamide derivs. as analgesics and antiinflammatories)

RN 766558-26-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-56-8 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho xy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-55-7
CMF C25 H42 N4 O5 S



CM 2

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-74-0 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-73-9
CMF C28 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-76-2 CAPLUS
CN Piperazine, 1-(1-ethyl-4-piperidinyl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-75-1
CMF C25 H42 N4 O5 S

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-60-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-59-1
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-68-2 CAPLUS
CN Piperazine, 1-[[2-[ethyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino]etho xy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-67-1
CMF C27 H44 N4 O5 S





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-78-4 CAPLUS
CN Piperazine, 1-[1-(1,1-dimethylethyl)-4-piperidinyl]-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-77-3
CMF C27 H46 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-84-2 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]eth oxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-83-1

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-89-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl](1-methylethyl)amino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-88-6
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-91-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxy]acetyl]-4-(1-ethyl-4-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-96-6
CMF C23 H36 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-01-6 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1,2,2,6,6-pentamethyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-00-5
CMF C28 H48 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 775285-90-0
CMF C26 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-95-5 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methoxyphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775285-94-4
CMF C22 H34 Cl2 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775285-97-7 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-methoxyphenyl)sulfonyl]methylamino]eth

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 775286-05-0 CAPLUS
CN Piperazine, 1-(8-ethyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-04-9
CMF C27 H44 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-09-4 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-[8-(1-methylethyl)-8-azabicyclo[3.2.1]oct-3-yl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-08-3
CMF C28 H46 N4 O5 S



L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-21-0 CAPLUS
CN Piperazine, 1-[[2-[[(2,6-dichloro-4-fluorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-20-9
CMF C21 H31 Cl2 F N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-22-1 CAPLUS
CN Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-23-2 CAPLUS
CN Piperazine, 1-[[2-[[(4-bromo-2,6-dichlorophenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-26-5 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 775286-27-6 CAPLUS
CN Piperazine, 1-[[2-[[(2,4-dichloro-6-methylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-26-5
CMF C22 H34 Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-28-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 1

CRN 775286-22-1
CMF C21 H31 Br Cl2 N4 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775286-24-3 CAPLUS
CN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 775286-25-4 CAPLUS
CN Piperazine, 1-(1-methyl-4-piperidinyl)-4-[[2-[methyl[(2,4,6-trichlorophenyl)sulfonyl]amino]ethoxy]acetyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-24-3
CMF C21 H31 Cl3 N4 O4 S



CM 2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 775286-29-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 775286-28-7
CMF C25 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 775287-67-7 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 775287-68-8 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 775288-70-5P, 4-[4-[[2-[[(4-Methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazine- and piperidine-containing benzenesulfonamide derivs. as analgesics and antiinflammatories)
RN 775288-70-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:800854 CAPLUS
DOCUMENT NUMBER: 141:314016
TITLE: Preparation of benzenesulfonamides as Bradykinin B1 receptors antagonists for treatment of pain and inflammation
INVENTOR(S): Barth, Martine; Bondoux, Michel; Dodey, Pierre; Massardier, Christine; Thomas, Didier; Luccarini, Jean Michel
PATENT ASSIGNEE(S): Laboratoires Fournier S.A., Fr.
SOURCE: Fr. Demande, 27 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2852958	A1	20041001	FR 2003-3602	20030325
FR 2852958	B1	20050624		
AU 2004226197	A1	20041014	AU 2004-226197	20040324
CA 2519110	A1	20041014	CA 2004-2519110	20040324
WO 2004087700	A1	20041014	WO 2004-FR723	20040324
WO 2004087700	A8	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1606288	A1	20051221	EP 2004-742333	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008689	A	20060328	BR 2004-8689	20040324
CN 1764661	A	20060426	CN 2004-80007762	20040324
JP 2006521333	T	20060921	JP 2006-505749	20040324
NO 2005004361	A	20051101	NO 2005-4361	20050920

PRIORITY APPLN. INFO.: FR 2003-3602 A 20030325
FR 2003-4530 A 20030411
WO 2004-FR723 A 20040324

OTHER SOURCE(S): MARPAT 141:314016
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1, R2, R3 = independently H, halo, alkyl, alkoxy, CF3, OCF3; Y = CH2CONHCH2, saturated alkylene chain interrupted by O or unsatn.; A = a bond, (CH2)m; R = saturated N-containing heterocycle selected
from pyrrolidine, morpholine, piperidine, quinuclidine, tropane, or dialkylamino, etc.; X = (CH2)p; m, p = independently 2-3; and their acid addition salts] were prepared as Bradykinin B1 receptor antagonists for

treatment of pain, inflammation. A 4-step synthesis for benzenesulfonamide II•2TFA is given. Selected I inhibited the second phase of licking response by 40 to 43% in a test of pain induced by formalin in mice. I inhibited Kallidin (a homolog of bradykinin)-induced contraction of isolated human umbilical vein, with a pKB > 7.

IT 766558-26-3P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide bistrifluoroacetate 766558-28-5P, 4-Methoxy-N-methyl-2,6-dimethyl-N-[2-[2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Bradykinin B1 receptor antagonist; preparation of benzenesulfonamides as Bradykinin B1 receptor antagonists for treatment of pain and inflammation)
RN 766558-26-3 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(1-methyl-4-piperidinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-25-2
CMF C24 H40 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 766558-28-5 CAPLUS
CN Piperazine, 1-[[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 766558-27-4
CMF C26 H42 N4 O5 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.48	186.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 10:55:53 ON 10 JUL 2007